Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

BACKGROUND: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Muñoz, Alfonso, Gallego, Elena, de Luque, Vanessa, Pérez-Rivas, Luís G, Vicioso, Luís, Ribelles, Nuria, Lozano, José, Alba, Emilio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868051/
https://www.ncbi.nlm.nih.gov/pubmed/20385028
http://dx.doi.org/10.1186/1471-2407-10-136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868051/
https://www.ncbi.nlm.nih.gov/pubmed/20385028
http://dx.doi.org/10.1186/1471-2407-10-136

Ejemplares similares